US · ATEC · MEDICAL - DEVICES
Alphatec Holdings, Inc. (ATEC) intrinsic value and stock valuation
$6.68as of 2026-11-21 · Mkt cap 1.47B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Alphatec Holdings, Inc. DCF and intrinsic value
InvestorsCraft values ATEC with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ATEC’s statements →
Alphatec Holdings, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Scholar Rock Holding Corporation (SRRK) $48.13
- LivaNova PLC (LIVN) $90.73
- Adaptive Biotechnologies Corporation (ADPT) $27.93
- Legend Biotech Corporation (LEGN) $15.25
- IDEAYA Biosciences, Inc. (IDYA) $25.56
- Disc Medicine, Inc. (IRON) $75.14
- Heartflow, Inc. Common Stock (HTFL) $46.69
- Zai Lab Limited (ZLAB) $21.03
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $764.2M | $611.6M | $482.3M | $350.9M | $243.2M |
| Operating income | -$-82.13M | -$-136.17M | -$-173.4M | -$-146.97M | -$-128.06M |
| Net income | -$-143.36M | -$-162.12M | -$-186.64M | -$-151.29M | -$-143.03M |
| EPSd | -$-955.35K | -$-1.13M | -$-1.54M | -$-1.46M | -$-1.49M |
| Operating cash flow | $45.2M | -$-44.65M | -$-78.48M | -$-75.13M | -$-73.32M |
| Capital expenditure | -$-42.45M | -$-93.14M | -$-86.97M | -$-58.28M | -$-68.54M |
| Free cash flow | $2.78M | -$-137.79M | -$-165.46M | -$-133.41M | -$-141.86M |
| Total assets | $791.2M | $775.7M | $805.2M | $521M | $572.1M |
| Total debt | $620M | $609.9M | $541.7M | $395.9M | $355.4M |
| Net debt | $459.1M | $471.1M | $320.7M | $311.2M | $168.2M |
| Total equity | $36M | $9.43M | $101.7M | -$-34.67M | $79.4M |
| Cash and short-term investments | $160.8M | $138.8M | $221M | $84.7M | $187.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $764.2M | $611.6M | $482.3M | $350.9M | $243.2M |
| Cost of revenue | $232.3M | $187.3M | $172.1M | $117.8M | $85.5M |
| Gross profit | $531.9M | $424.3M | $310.2M | $233.1M | $157.8M |
| Research and development expenses | $76.3M | $80.7M | $70.1M | $44M | $32M |
| Selling, general and administrative expenses | $498.5M | $450.2M | $374.1M | $300M | $229.3M |
| Other expenses | $39.2M | $29.5M | $39.4M | $36M | $24.5M |
| Operating expenses | $614M | $560.4M | $483.6M | $380M | $285.8M |
| Cost and expenses | $846.3M | $747.7M | $655.7M | $497.8M | $371.3M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $21.1M | $24.9M | $16.6M | $5.5M | $7.11M |
| Depreciation and amortization | $82.6M | $83.3M | $59.7M | $43.9M | $30.2M |
| Ebitda | -$-39.7M | -$-53.87M | -$-110.59M | -$-102.58M | -$-106.88M |
| Operating income | -$-82.13M | -$-136.17M | -$-173.4M | -$-146.97M | -$-128.06M |
| Total other income/expenses, net | -$-61.27M | -$-25.9M | -$-13.52M | -$-5.03M | -$-16.11M |
| Income before tax | -$-143.4M | -$-162.07M | -$-186.91M | -$-152.01M | -$-144.16M |
| Income tax expense | -$-40K | $50K | -$-280K | -$-720K | -$-1.13M |
| Net income | -$-143.36M | -$-162.12M | -$-186.64M | -$-151.29M | -$-143.03M |
| Weighted average shares outstanding | $150.1M | $143M | $121.2M | $103.4M | $96.2M |
| Weighted average diluted shares outstanding | $150.1M | $143M | $121.2M | $103.4M | $96.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $160.8M | $138.8M | $221M | $84.7M | $187.3M |
| Net receivables | $97.3M | $83M | $72.6M | $60.1M | $41.9M |
| Inventory | $169.4M | $175.3M | $136.8M | $101.5M | $91.7M |
| Total current assets | $450.9M | $417.4M | $451.1M | $255.6M | $331.2M |
| Property, plant and equipment, net | $166.6M | $191.1M | $176.3M | $130.3M | $112.7M |
| Goodwill and intangible assets | $168.7M | $164.5M | $175.5M | $130.2M | $125M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $340.3M | $358.3M | $354.1M | $265.3M | $240.9M |
| Total assets | $791.2M | $775.7M | $805.2M | $521M | $572.1M |
| Accounts payable | $40.9M | $53M | $49M | $34.7M | $25.7M |
| Short-term debt | $70.8M | $8.11M | $6.97M | $19.8M | $4.55M |
| Deferred revenue | $10.4M | $10.5M | $13.9M | $12M | $15.3M |
| Total current liabilities | $219.2M | $153M | $157.6M | $138.9M | $101.1M |
| Long-term debt | $549.1M | $601.8M | $534.7M | $376.1M | $350.9M |
| Deferred revenue, non-current | $2.18M | $3.13M | $2.56M | $3.05M | $2.9M |
| Total non-current liabilities | $536M | $613.3M | $545.9M | $416.8M | $391.5M |
| Capital lease obligations | $23.9M | $33.8M | $28.8M | $31.4M | $28.6M |
| Total liabilities | $755.2M | $766.3M | $703.5M | $555.6M | $492.6M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-1.42B | -$-1.28B | -$-1.12B | -$-932.32M | -$-782.33M |
| Accumulated other comprehensive income (loss) | -$-4.43M | -$-13.68M | -$-8.32M | -$-10.79M | -$-5.99M |
| Total equity | $36M | $9.43M | $101.7M | -$-34.67M | $79.4M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $620M | $609.9M | $541.7M | $395.9M | $355.4M |
| Net debt | $459.1M | $471.1M | $320.7M | $311.2M | $168.2M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-143.36M | -$-162.12M | -$-186.64M | -$-151.29M | -$-143.03M |
| Depreciation and amortization | $105.1M | $83.3M | $59.7M | $43.9M | $30.2M |
| Stock-based compensation | $73.7M | $73.3M | $81.2M | $40.6M | $36.5M |
| Change in working capital | -$-20.13M | -$-67.27M | -$-54.18M | -$-23.94M | -$-25.05M |
| Accounts receivable | -$-21.88M | -$-14.59M | -$-12.79M | -$-18.83M | -$-10.14M |
| Inventory | $13.5M | -$-54.66M | -$-45.56M | -$-20.7M | -$-27.75M |
| Accounts payable | -$-11.16M | $9.67M | $6.99M | $9.8M | $760K |
| Net cash provided by operating activities | $45.2M | -$-44.65M | -$-78.48M | -$-75.13M | -$-73.32M |
| Investments in property, plant and equipment | -$-42.45M | -$-83.22M | -$-80.51M | -$-49.45M | -$-68.54M |
| Acquisitions, net | $0.00 | $0.00 | -$-55M | $0.00 | -$-83.23M |
| Net cash used for investing activities | -$-53.41M | -$-93.14M | -$-141.97M | -$-58.28M | -$-157.76M |
| Common stock issued | $520K | -$-560K | $212.1M | -$-3.04M | $131.8M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | -$-30.96M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $30M | $56.2M | $356.9M | $31.2M | $312M |
| Net change in cash | $22M | -$-82.13M | $136.3M | -$-102.55M | $79.5M |
| Cash at end of period | $160.8M | $138.8M | $221M | $84.7M | $187.3M |
| Operating cash flow | $45.2M | -$-44.65M | -$-78.48M | -$-75.13M | -$-73.32M |
| Capital expenditure | -$-42.45M | -$-93.14M | -$-86.97M | -$-58.28M | -$-68.54M |
| Free cash flow | $2.78M | -$-137.79M | -$-165.46M | -$-133.41M | -$-141.86M |
Line items
Line items
Line items
About Alphatec Holdings, Inc.
Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX System, which is engineered to reduce the likelihood of nerve injury during surgery. For access and positioning, Alphatec offers systems such as the Sigma transforaminal lumbar interbody fusion pedicle-based access system, the Sigma PTP Access and Patient Positioning System, and the Squadron lateral retractor, all designed to optimize surgical outcomes. The company's robust line of spinal fixation devices features the Invictus Spinal Fixation System, capable of addressing various thoracolumbar pathologies, alongside its minimally invasive SingleStep System and adaptable Modular Fixation Systems, which enhance screw modularity. Further fixation options include the OsseoScrew system for spinal column restoration and the comprehensive Arsenal spinal fixation platform, catering to a spectrum of degenerative to deformity procedures. Alphatec also provides anterior lumbar plating solutions like the Aspida Anterior Lumbar Plating System for interbody fusion and the AMP Anti-Migration Plate, in addition to cervical fixation options such as the OCT Spinal Fixation System, the Trestle Luxe Anterior Cervical Plate System, and the Insignia Anterior Cervical Plate System. Its portfolio extends to interbody implants, including IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Implants. A comprehensive suite of biologics is also available, featuring Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. The company additionally offers EOS imaging products. Alphatec Holdings markets its diverse product range throughout the United States via a network of independent distributors and its own direct sales force. Established in 1990, the company's headquarters are located in Carlsbad, California.
- CEO
- Patrick S. Miles
- Employees
- 913
- Beta
- 0.85
Explore
Frequently asked questions
What is the intrinsic value of Alphatec Holdings, Inc. (ATEC)?
Alphatec Holdings, Inc. (ATEC) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ATEC undervalued?
ATEC trades at a price of $6.68 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.